Endothelial dysfunction (EDF) reflects pathophysiologicalchanges in the phenotype and functions of endothelial cells that result fromand/or contribute to a plethora of cardiovascular diseases. We review the roleof hydrogen sulfide (H2S) in the pathogenesis of EDF, one of thefastest advancing research topics. Conventionally treated as an environmentpollutant, H2S is also produced in endothelial cells and participatesin the fine regulation of endothelial integrity and functions. Disturbed H2Sbioavailability has been suggested to be a novel indicator of EDF progress andprognosis. EDF manifests in different forms in multiple pathologies, buttherapeutics aimed at remedying altered H2S bioavailability maybenefit all.
Bibliographical noteFunding: Natural Sciences and Engineering Research Council of Canada (NSERC); American Diabetes Association, the US National Institutes of Health (NIH), and the Shriners Hospitals for Children; UK Medical Research Council (MRC); British Heart Foundation (RG/09/001/25940), MRC (G0700288), Royal Society, and the European Commission; Aristeia grant (1436) that is co-financed by the European Commission (ESF) and Greek national funds through the Operational Program ‘Education and Lifelong Learning’; and OST (Cooperation in Science and Technology) Action BM1005 (ENOG: European Network on Gasotransmitters
- cystathionine gamma-lyase
- endothelium-derived hyperpolarizing factor
- heme oxygenase-1
- hydrogen sulfide
- nitric oxide